MBX Biosciences MBX 深 滬
已收盤 11-14 16:00:00 美东时间
24.79
+0.720
+2.99%
華盛通- 最 高25.90
- 今 開23.61
- 成交量 61.78万股
- 最 低 23.0701
- 昨 收 24.07
- 總市值 11.08亿
- 52周最高 26.47
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.8069
- 委 比 -75.85%
- 總股本 4470.19万
- 歷史最高 27.50
- 量 比 0.86
- 振 幅 11.76%
- 歷史最低 4.8069
- 每 手 1
- 風險率 4.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
MBX Biosciences Appoints Steven Hoerter as Executive Chair
MBX Biosciences, Inc. ( ($MBX) ) has shared an announcement. MBX Biosciences an...
11-06 21:28
MBX Biosciences Q3 EPS $(0.63) Beats $(0.70) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.70) by 9.87 percent. This is a 77.34 percent increase over losses of $(2.78) per share from the
11-06 21:14
TD Cowen Initiates Coverage On MBX Biosciences with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating.
11-04 20:28
MBX Biosciences to Participate in November Investor Conferences
<p>MBX Biosciences, a biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, announced that its CEO, Kent Hawryluk, and CMO, Sam Azoulay, will participate in four investor conferences in November 2025. The events include the Guggenheim Healthcare Innovation Conference in Boston, the Stifel Healthcare Conference in New York, the Jefferies Global Healthcare Conference in London, and a virtual su...
10-20 12:00
Tarrina Resources Limited Announces Name and ASX Code Change
My Foodie Box Limited ( ($AU:MBX) ) has shared an announcement. Tarrina Resourc...
10-16 15:52
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Truist Securities Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $50
Truist Securities analyst Srikripa Devarakonda initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $50.
10-15 19:37
MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim
In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy r...
10-06 20:15
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
MBX Biosciences, Inc. announced that its CEO, Kent Hawryluk, and Chief Medical Officer, Sam Azoulay, MD, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 10:00 a.m. ET. The live webcast and replay can be accessed via the company's website. MBX Biosciences focuses on developing peptide therapies for endocrine and metabolic disorders.
09-29 12:00
